A Multi-Center Adjuvant Trial of Outpatient Moderate-Dose Bolus Interleukin-2 for Renal Cancer
OBJECTIVES: I. Determine the disease free survival and overall survival of patients with
resected stage III or IV renal cancer treated with interleukin-2. II. Measure the degree of
rebound lymphocytosis generated by this regimen in these patients.
OUTLINE: This is an open label study. Patients receive interleukin-2 IV over 15-30 minutes
on 3 consecutive days weekly for 6 weeks, followed by 2 weeks of rest. Patients receive 2
treatment courses, each 8 weeks in duration. Patients are followed every 6 months until
PROJECTED ACCRUAL: A total of 20 patients will be accrued within 1 to 2 years.
Primary Purpose: Treatment
Datchen F. Tai, MD
Cancer Biotherapy Research Group
United States: Federal Government
|Bergan Mercy Medical Center||Omaha, Nebraska 68124|
|Baptist Regional Cancer Center - Knoxville||Knoxville, Tennessee 37901|
|Cancer Care Center for Southern Indiana||Bloomington, Indiana 47403|